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IL-18 was identified as a factor promoting IFN-
 
 
 
 produc-
tion (1) and it was originally called IFN-
 
 
 
–inducing factor
(IGIF). Further study indicated IL-18 had a structure related
to IL-1 (2) and later it was found that the IL-18 receptor re-
sembles that for IL-1 (3–4). IL-18, like IL-1 and agents in-
teracting with Toll receptors, signals via MyD88 which acti-
vates TNF receptor–associated factor and ultimately nuclear
factor 
 
 
 
B (5). Like IL-1, IL-18 is made as an inactive pre-
cursor that is cleaved by caspase-1 (interleukin-1–converting
enzyme) to produce active cytokine (6). Many cell types
have been reported to produce IL-18, including macro-
phages and dendritic cells (7); IL-18 mRNA or protein is also
seen in Kupffer cells (8), astrocytes and microglia (9), intesti-
nal and airway epithelial cells (10), and in kerotinocytes (11)
and osteoblasts (12). What induces IL-18 has not been ex-
tensively studied, but IL-18 is found after bacterial (13) and
viral (14) infection and, by inference, in many other infec-
tious diseases. IL-18 production from many cells is constitu-
tive or prolonged after induction (15). An important, but
not well-explored, role for IL-18 can also be inferred from
the fact that poxviruses make a homologue of IL-18–bind-
ing protein, a natural suppressor of IL-18 (16) and also an in-
hibitor of interleukin-1–converting enzyme (17).
 
Targets and Roles of IL-18.
 
Major targets of IL-18 in-
clude macrophages, NK cells (18), T cells (19), and perhaps
B cells (20). A major effect of IL-18 is the induction of cy-
tokine synthesis. IL-18 induces IFN-
 
 
 
 production from T
cells (1, 21), and IL-13 from NK cells and T cells (22), es-
pecially in concert with other signals (21).
Two papers in this issue (23, 24) provide compelling ev-
idence that IL-18 plays a key role in protection against in-
fectious disease and shed further light on the nature of that
role as well as the mechanism by which it occurs. Papers
from Neighbors et al. studying the role of IL-18 in protec-
tion against 
 
Listeria monocytogenes
 
 (
 
Listeria
 
), and from
Helmby et al. in protection against the helminth, 
 
Trichuris
muris
 
 (
 
Trichuris
 
),
 
 
 
both indicate that IL-18 promotes Th1
polarization of the immune response even when IFN-
 
 
 
 is
not involved, suggesting a broader range of IL-18 targets
and actions than was described previously. Together these
studies reenforce the concept of IL-18 as a highly pleio-
tropic, but decidedly pro-Th1 cytokine, that dramatically
enhances both innate and acquired immune responses.
IL-18 induces macrophages to produce IFN-
 
 
 
, but the
results of Neighbors and colleagues indicate that it also
stimulates macrophages to produce of TNF-
 
 
 
 and nitric
oxide (NO), and that both of these are critical in IL-18’s
important role in protection against 
 
Listeria 
 
(23). This is
likely to prove to be a key aspect of IL-18 action because
such a mechanism could explain the procytotoxic activities
of IL-18 (18, 19). Neighbors and colleagues have shown
convincingly, using both cytokine knockout and blocking
antibody studies, that the action of IL-18 is dominant over
those of IL-12 and IFN-
 
  
 
in promoting resistance to 
 
Liste-
ria
 
, and that the effect is largely independent of those cy-
tokines, but dependent on TNF-
 
 
 
. They also directly
demonstrate the ability of IL-18 to induce macrophages to
produce TNF-
 
 
 
 and NO (23). These results begin to ex-
plain the observations in the literature that IL-18 seems to
be required for protection against a broad range of patho-
gens including 
 
Mycobacteria
 
 (25), 
 
Salmonella 
 
(26), 
 
Shigella
 
(26), 
 
Leishmania
 
 (27), 
 
Staphylococci 
 
(28), and 
 
Cryptococci 
 
(29).
 
IL-18 and Cytokine Polarization.
 
Early studies of IL-18
stressed its IFN-
 
 
 
–inducing abilities and promoted its role as
an inducer of Th1 responses (1, 19, 20), but more recently a
number of studies and reviews have suggested IL-18 can
also enhance production of Th2 cytokines and promote IgE
synthesis (30, 31). The papers in this issue indicate that the
major in vivo role is likely to be weighted towards IL-18 in-
ducing a Th1 response. Not only did IL-18 mediate protec-
tion against 
 
Listeria
 
, but in the 
 
Trichuris 
 
model, the absence
of IL-18–converted B6 mice which were susceptible to low
doses of the helminth, to a highly resistant state that is more
profound than that seen in IL-12–deficient mice (24). In
contrast Balb/c mice, which are normally resistant to 
 
Tri-
churis
 
 via a mechanism dependent on IL-13– and IL-4–
mediated expulsion of the nematode, become susceptible after
IL-18 treatment. In both cases susceptibility correlates with
low IL-13 (not IL-4) levels. The authors conclude that IL-
18 plays a key role in gastrointestinal nematode infections
via downregulation of IL-13 (24). The authors also were
able to visualize very early production of IL-18 after infec-
tion in the intestine by macrophages and dendritic cells,
which correlates with the susceptible phenotype (24).
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The reason that IL-18 induces Th2 cytokines under
some circumstances remains unexplained, but these new
studies tip the balance in favor of a predominantly pro-Th1
action of IL-18. A cartoon summarizing the action of IL-18
in protection against infectious disease, derived from the
recent and earlier studies, is in Fig. 1.
 
Perspectives and Questions
 
One of the most novel activi-
ties of IL-18 is its ability to induce Th1 effectors to produce
IFN-
 
 
 
 in the absence of TCR signaling (21). IL-18 and IL-2
alone can induce prolonged IFN-
 
 
 
 protein synthesis and,
together with TCR triggering, there is a marked synergy
resulting in high levels of IFN-
 
 
 
 secreted for at least 5 d
(21). This is in marked contrast to the effects of TCR trig-
gering alone which results in only transient cytokine syn-
thesis. The prolonged presence of IFN-
 
 
 
 at sites of inflam-
mation is liable to result in very dramatic biological effects
both in the effector phase of the response but also in its
subsequent downregulation (32, 33). Thus prolonged IFN-
 
 
 
production could provide a source of IFN-
 
 
 
 that would be
available late in the immune response to help downregulate
excessive CD4 T cell expansion.
Finally, as IL-18 shares a common signaling pathway
with IL-1
 
 
 
 and other Toll receptor interacting compo-
nents, IL-1
 
 
 
 and agents signaling via toll receptors might
be expected to induce prolonged rather than transient
IFN-
 
 
 
 production. It would also be of interest to deter-
mine if the other cytokines produced in response to IL-18
also show prolonged induction.
The regulation of IL-18 production also deserves further
exploration. Some cells have been reported to make IL-18
constitutively (15), but certain infections apparently lead to
upregulation of production. The consensus seems to be
that macrophages and related cells are the major producers,
but what cells make IL-18 in different circumstances and
what conditions favor IL-18 production, processing, and
subsequent blocking by IL-18–binding protein deserve fur-
ther study.
 
Conclusions.
 
IL-18 is emerging as a powerful, pleiotropic
cytokine involved in determining the polarization of T cell
responses and whether the responses to infectious organ-
isms are protective or not. IL-18 is made by macrophages,
dendritic cells, perhaps lymphocytes, and by nonimmune
cells; and like IL-1, its actions are regulated by the require-
ment for proteinase cleavage and by blocking proteins, as
well as by the expression of its receptor by the variety of
potential targets. It has potent actions on macrophages, in-
ducing TNF production and its consequences as well as
NO production, on T cells and B cells inducing IFN-
 
 
 
 es-
pecially in synergy with other cytokine inducers including
IL-12 and Ag/APC. We are sure to hear much more about
IL-18 as a critical multipotent inducer of innate and ac-
quired immune responses.
Figure 1. 
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